Exploitation of NKG2C+ NK cells for immunotherapy of GBM cells is hampered by low abundance of NK cells in peripheral blood of donors when compared to T cells and furthermore, can be impeded by often inadequate frequencies of NKG2C+ cells in HCMV-seropositive donors. This evidence concerns the gene KLRC2 and glioblastoma.